Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation

作者
Miaomiao Wen,Jinghua Xia,Ying Sun,Xuejiao Wang,Xianghui Fu,Yanning Zhang,Zhipei Zhang,Yongan Zhou,Xiaofei Li
出处
期刊:Biologics: Targets & Therapy [Dove Medical Press]
卷期号:Volume 12: 183-190 被引量:25
标识
DOI:10.2147/btt.s169305
摘要

Purpose: Both epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, and the combination of EGFR-TKIs and chemotherapy has been used for advanced NSCLC patients; however, little is known about the efficacy of the direct comparison among them. Patients and methods: The demographic and clinical characteristics of 92 patients harboring advanced NSCLC with EGFR mutation were retrospectively reviewed. We evaluated the effects of EGFR-TKIs, chemotherapy, and EGFR-TKIs plus chemotherapy on advanced NSCLC patients with EGFR mutations, and the efficacy of combination of chemotherapy and EGFR-TKIs vs chemotherapy or EGFR-TKIs alone in advanced NSCLC patients was evaluated. Results: The statistical results showed that the intercalated combination of EGFR-TKIs plus chemotherapy significantly improved progression-free survival (PFS; HR, 1.76; 95% CI 1.03–3.01; P =0.036; median, 20.5 vs 16 months) compared with EGFR-TKI monotherapy, but no difference in overall survival (OS) was observed between these two groups (HR, 1.52; 95% CI 0.81–2.83; P =0.19; median, 36 vs 29 months). However, patients who received the combination of chemotherapy and EGFR-TKIs had longer PFS (HR, 2.78; 95% CI 1.57–4.93; P <0.0001; median, 20.5 vs 12 months) as well as OS (HR, 2.86; 95% CI 1.56–5.27; P =0.001; median, 36 vs 18 months) than those who received chemotherapy alone. Toxicities were mild among the three treatment groups. Rash and diarrhea were common adverse events (AEs) in the EGFR-TKI group, anemia and nausea in the chemotherapy group, and anemia and diarrhea in the combination group. Conclusion: This study demonstrated that the combination of chemotherapy with EGFR-TKIs as first-line treatment has a significant effect on PFS in patients with advanced NSCLC whose tumors harbor activating EGFR mutations. The combination treatment had more toxicity, but was clinically manageable. Keywords: non-small-cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitor, chemotherapy, adjuvant therapy, retrospective study

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大力一德完成签到,获得积分10
刚刚
今后的应助被细心的易文采纳,获得10
刚刚
悦悦发布了新的文献求助10
刚刚
彭于晏的应助被Yuwei采纳,获得10
刚刚
刚刚
hongzhihu完成签到,获得积分20
刚刚
落 风完成签到,获得积分10
刚刚
舒心的耷完成签到,获得积分10
1秒前
1秒前
香蕉觅云的应助被霁月采纳,获得10
1秒前
超级丸子完成签到,获得积分10
1秒前
优秀念柏完成签到,获得积分10
2秒前
2秒前
墨染完成签到,获得积分10
2秒前
研友_OWE完成签到,获得积分10
2秒前
凡人修仙传完成签到,获得积分10
2秒前
snow完成签到 ,获得积分10
3秒前
3秒前
Lucas的应助被碎觉觉采纳,获得10
3秒前
NexusExplorer的应助被Jenny采纳,获得10
3秒前
jerry完成签到,获得积分10
3秒前
可期完成签到,获得积分10
3秒前
完美世界的应助被今天采纳,获得10
3秒前
3秒前
hongzhihu发布了新的文献求助10
4秒前
一手灵魂完成签到,获得积分10
4秒前
别摆烂了完成签到,获得积分10
5秒前
Cc发布了新的文献求助10
5秒前
艺2333完成签到,获得积分10
5秒前
平常的夜安完成签到,获得积分20
5秒前
炙热觅海完成签到,获得积分10
5秒前
6秒前
7秒前
yuhanli给yuhanli的求助进行了留言
8秒前
潆星发布了新的文献求助10
8秒前
如水从平完成签到,获得积分10
8秒前
书意完成签到 ,获得积分10
8秒前
aaa发布了新的文献求助10
9秒前
cdercder的应助被单纯之柔采纳,获得10
9秒前
yichen发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253